Form D · Private Equity Fund

OrbiMed Asia Partners III, L.P.

New York, NY · CIK 0001685093

Offering snapshot reported Sep 6, 2017 · SEC filing

Reported sold: $540M
Investors reported: 97
Minimum accepted: $100K
First sale: Mar 1, 2017

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$431,530,000 → $539,960,000
Reported investors95 → 97
Minimum accepted$0 → $100,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 6, 2017	Amendment	$539,960,000	$108,430,000vs Jun 28, 2017	97	SEC filing
Jun 28, 2017	Amendment	$431,530,000	No comparison	95	SEC filing
Mar 1, 2017	Amendment	Yet to sell	No comparison	0	SEC filing
Feb 27, 2017	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $2.48M
Finders' fees: $0
Form D file number: 021-281414

Amount to be paid is based upon a percentage of capital raised.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
J.P. Morgan Securities LLC	79

Source: Form D, filed Sep 6, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

ORBIMED ASIA PARTNERS III, L.P.

Investment adviser: ORBIMED ADVISORS LLC

Gross asset value: $2.08B
Beneficial owners: 120
ADV minimum commitment: $10M

Reported in Form ADV on Aug 18, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator SS&C TECHNOLOGIES, INC. NEW YORK, New York, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor KPMG LLP NEW YORK, New York, United States

Custodian AFRASIA BANK LIMITED PORT LOUIS, Mauritius Related to adviser: No

Custodian CHINA INTERNATIONAL CAPITAL CORPORATION BEIJING, China Related to adviser: No

Custodian CHINA MERCHANTS BANK NEW YORK, New York, United States Related to adviser: No

Custodian CITIBANK (INDIA) N.A. MUMBAI, India Related to adviser: No

Custodian HAITONG SECURITIES SHANGHAI, China Related to adviser: No

Custodian JPMORGAN CHASE BANK, N.A. NEW YORK, New York, United States Related to adviser: No

Custodian SILICON VALLEY BANK NEWTON, Massachusetts, United States Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

KPMG LLP
PCAOB 185

JPMORGAN CHASE BANK, N.A.
LEI 7H6GLXDRUGQFU57RNE9

Filing source

Form ADV 2126532 · Aug 18, 2026 · Schedule D 7.B.(1), fund 805-8033855374

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Sven H. Borho	Director
Carl L. Gordon	Director
Samuel D. Isaly	Director
W. Carter Neild	Director
N/A Orbi Med Advisors Iii Limited	Executive, Promoter
N/A Orbi Med Asia Gp Iii, L.P.	Executive, Promoter
Sunny Sharma	Director
Jonathan T. Silverstein	Director
David G. Wang	Director
Jonathan Wang	Director

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

601 Lexington Avenue 54 Th Floor
New York, NY, 10022